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Melanoma is a very aggressive tumor that arises from melanocytes. Late stage and widely spread 
diseases do not respond to standard therapeutic approaches. The kallikrein-kinin system (KKS) 
participates in biological processes such as vasodilatation, pain and inflammatory response. However, 
the role of KKS in tumor formation and progression is not completely understood. The role of the 
host kinin B1 receptor in melanoma development was evaluated using a syngeneic melanoma model. 
Primary tumors and metastasis were respectively induced by injecting B16F10 melanoma cells, which 
are derived from C57BL/6 mice, subcutaneously or in the tail vein in wild type C57BL/6 and B1 receptor 
knockout mice (B1−/−). Tumors developed in B1−/− mice presented unfavorable prognostic factors such 
as increased incidence of ulceration, higher levels of IL-10, higher activation of proliferative pathways 
such as ERK1/2 and Akt, and increased mitotic index. Furthermore, in the metastasis model, B1−/− 
mice developed larger metastatic colonies in the lung and lower CD8+immune effector cells when 
compared with WT animals. Altogether, our results provide evidences that B1−/− animals developed 
primary tumors with multiple features associated with poor prognosis and unfavorable metastatic 
onset, indicating that the B1 receptor may contribute to improve the host response against melanoma 
progression.
Melanoma is a very aggressive tumor that arises from melanocytes; a cell type specialized in producing the skin 
protective pigment melanin. Although early stage-diagnosed disease is highly curable by surgical removal of the 
malignancy, late stage and widely spread diseases do not respond to standard therapeutic approaches, such as 
chemotherapies and radiotherapies. Consequently, the survival rate of patients drops from 90% in early stages 
to only 10% in late-stage melanoma, with a recurrence risk of up to 60% in the last case1. Activating mutations 
in proto-oncogenes or inactivating mutations in tumor suppressor genes are major players in tumor formation, 
and indeed, BRAF mutations have been shown to be highly prevalent among melanomas2,3. Although the block-
ade of this pathway improved patient outcome, many cases of tumor relapse were reported4. Furthermore, in 
many cases, added to mutations, tumors require a permissive microenvironment to confer a complete malignant 
and invasive phenotype5,6. The ability to change its microenvironment and hijack host pro-inflammatory and 
migratory signaling capacity is crucial to promote tumor sustained proliferative signals, induce angiogenesis and 
promote tumor-related inflammation. This dynamic interface between host and tumor cells is still poorly under-
stood, however it has been shown to actively modulate tumor aggressiveness7.
The kallikrein-kinin system (KKS) is responsible for several biological processes, such as vasodilatation/vaso-
constriction, modulation of pain, inflammatory response, contraction/relaxation of smooth muscles and cell prolif-
eration8. The two main receptors of the KKS are kinin B1 and kinin B2 receptors. While the kinin B2 receptor is 
constitutively expressed under physiological conditions and binds with high affinity to bradykinin (BK) and kallidin 
(KD), the expression of the kinin B1 receptor is inducible by a range of factors that include exposure to agonists, such as 
des-Arg9-BK (DABK) or des-Arg10-KD (DAKD), pathological conditions, inflammation, activation of kinin B2 recep-
tor, as well as other factors that are able to engage and activate the transcription factors CREB, AP1 and NFκ B9,10,11.
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Regarding tumor formation and progression, the role of KKS in this pathology is still poorly understood. The 
expression of kinin B1 and B2 receptors has been described in many tumor types, and several reports have shown 
a pro-tumor role of kinin B2 receptor12–15. For the kinin B1 receptor, a much less clear scenario appears. Although 
its activation has been related to induction of cell proliferation and primary tumor growth in lung and prostate 
cancer xenografts16, a recent report from our group showed that activation of kinin B1 receptor in tumor cells 
reduces melanoma progression, significantly decreasing metastasis and therefore improving animal survival17. 
Regarding the contribution of the B1 receptor present in the host, there is no data in the literature describing its 
role during melanoma development and metastasis. Considering that the tumor microenvironment has been 
shown to play a major role in tumor growth and progression and that kinin B1 receptor activation in tumor 
decreased tumor burden and extended animal life span, we hypothesized that kinin B1 receptor in the tumor 
microenvironment could contribute to a host protective response against melanoma.
In the present work we investigated whether kinin B1 receptor present in the tumor microenvironment could 
also contribute to the host response during melanoma progression. To that, we took advantage of B16F10 mel-
anoma cells, which is a well validated model for both primary tumor and pulmonary metastasis18–20. Using the 
kinin B1 knockout mice (B1−/−) and a syngeneic tumor model, we show that the absence of the host kinin B1 
receptor gives rise to melanomas with higher incidence of ulceration, decreased immune response, higher mitotic 
index and larger metastatic colonies, all of them markers of poor prognosis21,22.
Results
Ablation of the kinin B1 receptor in mice leads to a higher incidence of ulcerated tumors. To 
evaluate the contribution of the host kinin B1 receptor in the tumor microenvironment for melanoma growth, we 
performed a melanoma implantation assay by inoculating 300,000 B16F10 cells into the dorsal superior region 
of WT and B1−/− mice. Tumor growth was monitored daily. Results show that in both groups, tumors remained 
quiescent for a long period of time before growing extremely rapidly during the last 5 days of the experiment to 
reach maximal volume at day 22 (Fig. 1a). As we observed very similar kinetic profiles of tumor growth for both 
animal groups, and considering that kinin B1 receptor is induced under pathological conditions, we performed 
the analyses at the end point of the tumor growth curve, which would allow more time for host response and 
kinin B1 receptor expression to be induced in the WT mice and subsequent engagement in the possible down-
stream responses and outcomes. Despite that the kinetics of tumor progression (Fig. 1a) and tumor weight at the 
experiment end point (Fig. 1b) were not significantly altered in B1-deficient mice, significant differences between 
tumors from WT and B1−/− mice were found regarding one of the key prognostic markers for melanomas, which 
is ulceration. The presence of ulceration in the primary tumor is a strong indicator of poor prognosis and it is 
considered one of the most powerful survival predictor for melanoma patients, along with tumor thickness and 
mitotic rate21,22. According to the American Joint Committee on Cancer (AJCC), since 2009 the presence of ulcer-
ation has to be considered for the T-classification of primary melanomas. Non-ulcerated tumors are classified as 
Ta while ulcerated tumors are classified as Tb. Here, we considered ulceration when a disrupted epidermal conti-
nuity was observed around the tumor area23, as shown in Fig. 1c. Approximately 50% of the tumors that developed 
in the B1−/− mice were ulcerated, compared to only 10% of the tumors in the WT animals (Fig. 1d), although there 
was no difference in the size of the ulcerated lesions. It is important to note that histological analysis of skin from 
kinin B1−/− mice revealed no alteration in the skin architecture when compared with WT animals (Fig. 1e). These 
results suggest that tumors developing in a B1-deficient microenvironment may show similar growth rate, but 
increased aggressiveness as compared to tumors developing in WT mice. Taken together, melanomas from kinin 
B1 receptor deficient mice could be classified in a different stage group such as more aggressive melanomas, sug-
gesting that the presence of the B1 receptor in the host may contribute to a protective response against melanoma.
Ablation of the kinin B1 receptor in mice does not affect melanoma vascularization. Angiogenesis is a 
crucial process during tumor formation and therefore is considered one of the hallmarks in cancer. Although 
it is not a direct prognostic marker in melanomas, the ability to build a vascular network allows glucose and 
oxygen supply to the growing tumor24. We compared tumor vascularization between melanomas from WT and 
B1−/− mice. Representative images from histological analysis of the tumors and quantification of the number of 
vessels per high magnification field showed no significant difference in the tumor vascularization between both 
groups (Fig. 2a,b). As VEGF is a key player in angiogenesis inducing endothelial cells proliferation25 as well as 
vascular permeability26 we analyzed VEGF mRNA expression by real-time PCR and protein expression by west-
ern blotting in tumors from WT and B1−/− mice. As seen in Fig. 2c,d, both groups express similar levels of VEGF, 
suggesting that host kinin B1 receptor contributes neither to neovascularization nor to VEGF-dependent vascular 
permeability during melanoma development.
Kinin B1 receptor-knockout mice show tumors with increased IL-10 levels. As high immune 
response has been correlated with good prognosis in melanomas27 and activation of B1 receptor in tumor cells 
has been shown to decrease melanoma development17, we hypothesized that absence of host kinin B1 receptor 
could potentially impact cytokine production in the tumor area, which ultimately would lead to altered host 
immune response. Therefore, we evaluated cytokine expression profiles in tumors from WT and B1−/− mice. As 
seen in Fig. 2e, although there are no significant changes in the expression of pro-inflammatory cytokines, such 
as TNF-α , TGF-β , INF-γ and IL-6, we found a significant overexpression of the anti-inflammatory cytokine 
IL-10 within the tumor mass of B1−/− mice. This result suggest that in the absence of host kinin B1 receptor, 
tumors grow in an IL-10 enriched microenvironment, which possibly contributes to down-regulate host immune 
response28.
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Figure 1. Ablation of the host kinin B1 receptor increases skin ulceration. (a) Tumor growth curve of wild 
type (WT) and kinin B1 receptor-knockout mice (B1−/−) after receiving subcutaneous injection of 300,000 
B16F10 cells. (b) Tumor weight 22 days after B16F10 cells inoculation; WT: n = 19, B1−/−: n = 17, p = 0.1758. 
(c) Representative images of C57BL/6 animals with non-ulcerated and ulcerated B16F10 melanomas.  
(d) Percentage of animals that showed a breakdown of the skin over the melanoma (ulcerated lesions) 22 days 
after receiving subcutaneous injection of 300,000 B16F10 cells. Data are expressed as a percentage ± SEM; WT: 
n = 19, B1−/−: n = 17, *p = 0.0197. (e) Representative images from histological analysis of skin of adult mice 
showing no changes in skin architecture between wild type (WT) and kinin B1 receptor-knockout mice (B1−/−); 
n = 6.
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Figure 2. Ablation of the host kinin B1 receptor does not alter melanoma vascularization but presents 
increased IL-10 levels. (a) Representative images from histological analysis showing similar vascular network 
(black arrows) of tumors developed in wild type (WT) and kinin B1 receptor-knockout mice (B1−/−) 22 
days after melanoma cells inoculation. (b) Quantification of the number of vessels in tumors from WT and 
B1−/− mice in ten different high magnification fields. Data are expressed as number of vessels ± SEM; n = 8, 
p = 0.1127. (c) Quantitative real-time PCR analysis of VEGF mRNA expression in B16F10 tumors from WT 
and B1−/− mice. Data are expressed as fold of change from relative expression of VEGF/Cyclophilin B ± SEM; 
n = 12, p = 0.3246. (d) VEGF expression was accessed by western blotting 22 days after tumor cells implantation 
in wild type (WT) and B1 receptor-knockout mice (B1−/−). Data are expressed as fold of change from relative 
expression of the VEGF/β -actin ± SEM; n = 5; p = 0.1074. (e) Analysis of cytokine profile in B16F10 tumors 
from wild type (WT) and kinin B1 receptor- knockout mice (B1−/−) 22 days after subcutaneous injection of 
melanoma cells. Experiments were performed by quantitative real-time PCR. Data are expressed as fold of 
change from relative expression of target gene/Cyclophilin B ± SEM; n = 12, *p = 0.0107.
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Ablation of the kinin B1 receptor in mice increases activation of proliferative pathways and 
mitotic index in melanoma. Among different prognostic factors used to classify tumor aggressiveness, the 
mitotic index is the most widely used and accepted in the clinic29. To gain further insights regarding the role of 
host kinin B1 receptor in melanoma tumor growth and progression, we analyzed activation of proliferative path-
ways. As seen in Fig. 3a, ERK1/2 phosphorylation is increased in tumors from B1−/− mice. Moreover, PI3K-Akt 
pathway, another important survival/proliferative pathway was also significantly more activated in tumors from 
B1−/− as evaluated from Akt phosphorylation at Ser308 (Fig. 3b). Histological analysis of the tumors from WT and 
B1−/− mice support our molecular analysis and show a higher incidence of cells undergoing mitosis in tumors 
from B1−/− mice when compared to WT (Fig. 3c). To calculate the mitotic index of tumors from WT and B1−/− 
mice, a pathologist analyzed tumor samples from WT and B1−/− mice and counted the number of cells in mitosis 
in 10 non-coincident high magnification fields. Histopathological analysis showed a significant higher number of 
cells undergoing mitosis in tumors from B1−/− mice (Fig. 3d), confirming the more aggressive feature of tumors 
developed in the absence of kinin B1 receptor.
Figure 3. Ablation of the host kinin B1 receptor increases activation of proliferative pathways and mitotic 
index in melanoma. Activation of proliferative pathway was accessed by western blotting 22 days after tumor 
cells implantation in wild type (WT) and B1 receptor-knockout mice (B1−/−). (a) Phosphorylation/activation of 
ERK and (b) AKT, are increased in tumors from B1−/− mice. Data are expressed as fold of change from relative 
expression of the phosphorylated/total form of the protein ± SEM; n = 8; **p = 0.0028, *p = 0.0120.  
(c) Representative images from histological analysis showing a higher number of cells in mitosis (black arrows) 
in tumors from B1−/−. (d) Quantification of the number of cells in mitosis in tumors from WT and B1−/− mice 
in ten different high magnification fields. Data are expressed as number of cells ± SEM; n = 8; #p = 0.0098.
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Melanoma metastases analysis in kinin B1 receptor-knockout mice shows larger colonies in 
the lung, with increased vascularization and decreased infiltration of effector CD8+T cells. To 
study whether host kinin B1 receptor could play a protective role in metastatic melanoma, B16F10 melanoma 
cells were delivered directly into the blood flow of WT and B1−/− mice by tail vein injection, and within 30 days 
after injection lung metastases were screened. As shown in Fig. 4a, there was no significant difference between the 
number of colonies present in the lungs of WT and B1−/− mice. However, the incidence of large melanoma colo-
nies in the lungs was 3 fold higher in B1−/− mice compared with the WT group (Fig. 4b). Corroborating this data, 
histological analysis revealed a significant increase in the number of blood vessels in the lungs from B1−/− mice 
(Fig. 4c), which suggests that absence of host kinin B1 receptor confers growth advantages to melanoma in the 
lung. We performed full autopsies and as expected for this model30, we only found metastasis in the lungs with no 
incidence of tumors spread into other organs. Given that host immune response is a key component during tumor 
growth and progression31, that high immune response has been correlated with better prognosis in melanomas27, 
and that our primary tumor data showed a remarkable increase in tumor expression of the anti-inflammatory 
Figure 4. Kinin B1 receptor in the host in involved in colony growth and immune response during 
metastasis progression. Lung metastasis was induced by the injection of B16F10 cells in the tail vein of wild 
type (WT) and kinin B1 receptor-knockout mice (B1−/−) WT: n = 11, B1−/−: n = 8. (a) Number of colonies 
stablished in the lung after 30 days of B16F10 cells injection; p = 0.2416. (b) Percentage of colonies with 
diameter higher than 1 mm. (c) Histological analysis showing higher number of blood vessels (black arrows) 
in metastatic lungs of B1−/− compared to WT mice. Data are expressed as number of vessels ± SEM; n = 8, 
*p = 0.0036. (d) Immunohistochemistry analysis of CD4+and (e) CD8+cells in the metastatic lung from WT 
and B1−/− mice. Data are expressed as positive cells ± SEM #p = 0.0132; n = 6. (c–e) Left panel: representative 
images, right panel: quantification of ten different high magnification fields.
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cytokine IL-10 when host B1 receptor is absent (Fig. 2e), we investigated whether the content of immune cells in 
metastatic lungs of WT and B1−/− mice was altered. Using immunohistochemistry assay, we analyzed the content 
of CD4+T cells as well as of the effector CD8+T cells in the metastatic lungs of WT and B1−/− mice. Interestingly, 
we found effector CD8+T cells to be significantly reduced in the lungs of B1−/− mice (Fig. 4e). In contrast we 
found that both groups presented similar levels of CD4+T cells in the lungs (Fig. 4d), which suggests that absence 
of host kinin B1 receptor did not impair CD4+T cell migration to the metastatic lung but increases CD8+cells. 
Moreover, we assessed IL-10 expression levels in the lungs, but no significant differences were found when com-
paring wild type and B1−/− mice (Supplementary Figure S1). Taken together our data show that loss of host kinin 
B1 receptor affects two major cancer-related events in metastatic melanomas: tumor cell proliferation and host 
anti-tumor immune response. Therefore, our data suggest that host kinin B1 receptor may play a role against 
tumor progression during melanoma metastasis formation.
Discussion
The expression of KKS components has been reported in several malignancies. For instance, PSA (prostate spe-
cific antigen), a widely used diagnostic marker for prostate tumors32, is a kallikrein. Recent studies have started 
uncovering the underling mechanisms by which the KKS is involved in tumorigenesis; however, the role of kinin 
receptors in this process is not fully understood. The KKS is directly affected by class I anti-hypertensive drugs, 
since the blockade of ACE/kininase II promotes accumulation of kinin receptors ligands. Considering the wide-
spread usage of ACE inhibitors in the treatment of cardiovascular and renal diseases33, understanding the role 
of kinin receptors in tumorigenesis may lead to better therapeutic approaches. Although, there are indications 
that the antagonism of the kinin B1 receptor decreases cell proliferation in different tumor cells12, nothing can 
be found in the literature regarding the role of the kinin B1 receptor present in the host during tumor develop-
ment. Here, we bring evidence that the host kinin B1 receptor may contribute towards a protective role against 
melanoma progression. Using a syngeneic melanoma model, we induced melanoma in WT and B1−/− mice and 
observed that B1−/− mice tumors showed higher levels of the anti-inflammatory cytokine IL-10, increased inci-
dence of ulceration as well as increased mitotic index; all features that are considered as markers of poorer prog-
nosis for melanoma patients21. Moreover, using an experimental metastasis model, we showed that B−/− mice 
developed larger lung metastatic colonies, increased lung vascularization, and decreased infiltration of anti-tumor 
CD8+T cells as compared to WT animals.
The KKS and its vasoactive peptides BK, desArg9-BK, KD and desArg10-KD play important roles in vaso-
dilation, smooth muscle contraction, and inflammation. Although the connection between inflammation and 
cancer was proposed in the 19th century by Rudolph Virchow34, and has recently been considered a hallmark of 
cancer6, the role played by immune cells within the tumor area is still not fully understood. While the presence 
of inflammatory cells has been associated with poor prognosis in many solid tumors35, they are also essential 
for host anti-tumor immune response. Our data show that in the absence of the host kinin B1 receptor, the 
expression of pro-inflammatory cytokines such as TNF-α , IFN-γ , IL-6 and TGF-β are unchanged in primary 
tumors. However, we observed that the anti-inflammatory cytokine IL-10 was upregulated, promoting an IL-10 
preponderant microenvironment within the tumor mass. Considering that activation of B1 receptor triggers 
pro-inflammatory responses36,37, we believe that the lower levels of IL-10 in primary tumors from WT animals 
might be due to the pro-inflammatory action of the WT host B1 receptor, which in this case can counteract the 
anti-inflammatory response within the tumor. Regarding metastasis, we did not find significant differences of 
IL-10 expression in lungs with metastatic melanoma colonies from WT and B1−/− animals. It is however impor-
tant to note that, although the majority of cells from primary tumor samples are comprised of tumor derived cells, 
small tumor colonies from lungs are processed with a larger area of host lung parenchyma. In fact, local IL-10 
affects host immune response in many levels, including decrease in CD8+T-cell-mediated tumor lysis, down reg-
ulation of major histocompatibility complex (MHC) class II and co-stimulatory molecules in dendritic cells38,39. 
Moreover, the kinin B1 receptor has been already associated with the migration of immune cells to injured tis-
sues40. In our study, we observed that lungs from WT animals presented lower number of vessels compared to 
B1 receptor deficient mice. The less vascularized microenvironment along with increased CD8+T-cell infiltration 
in the lungs, may have at least partially contributed to arrest colony growth in the lungs, resulting in the smaller 
colony size phenotype observed in WT animals.
The AJCC serves as the dominant staging system for melanomas, which is pivotal in determining prognosis 
and appropriate treatment. For primary tumor evaluation, since 2009 the AJCC takes into account ulceration and 
mitotic activity for the pathological assessment; and the presence of both parameters is directly correlated with 
poorer prognosis41–43. Our data show that in the absence of the host kinin B1 receptor the incidence of ulcerated 
tumors increased from 10% in WT to 50% in B1−/− mice. BRAF mutations are highly prevalent in melanomas, 
suggesting that this type of tumor, between other pathways, is regulated by the MAPK pathway. In fact, the use 
of BRAF inhibitors have been approved to treatment of melanoma and, although recurrence has been reported, 
most of the cases are associated with the plasticity of the tumors to reactivate MAPK or upregulate the alternative 
pathway, PI3K/Akt44. Interestingly, our data show that the absence of host kinin B1 receptor allows up-regulation 
of MAPK/ERK and PI3K/Akt pathways, which correlates with the increased mitotic index in tumors from B1−/−. 
These results corroborate our hypothesis that the absence of the B1 receptor in the microenvironment may 
increase tumor anti-inflammatory responses, depressing the immune system and consequently providing better 
conditions for cell proliferation and tumor aggressiveness. Studies with melanoma patients showed that higher 
mitotic rate is correlated with ulceration and thicker melanomas45. Our data show that B1−/− mice developed 
tumors with higher mitotic index along with higher ulceration than WT mice, while both groups share similar 
tumor size. It is well established that multiple factors contribute to the primary tumor size, especially the ratio 
between tumor cells proliferation and death, which can induce feedback loops modulating growth, angiogenesis, 
host immune response and ultimately, tumor progression and metastasis. In this context, one possibility is that 
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tumors from host deficient kinin B1 receptor, which presented 25% higher mitosis index than WT (Fig. 3c,d) but 
similar primary tumor volume (Fig. 1a,b) and similar vascular network density (Fig. 2a,b), could be in shortage 
of nutrients and oxygen supply, which could ultimately be a limiting factor for primary tumor growth. However, 
even with a scarcity of nutrients and oxygen supply, the alterations caused by the absence of the kinin B1 recep-
tor in the lung microenvironment would be sufficient to modulate tumor-host interaction and favor metastasis. 
Indeed, we found that lung colonization by melanoma cells in the metastatic model presented larger colonies, 
suggesting that despite of similar primary tumors volume; kinin B1 receptor deficient mice give rise to more 
aggressive and metastatic tumors than WT mice.
Several reports have shown expression of kinin receptor in tumors and tumor cell lines14,15,46, and the use of 
antagonists, mainly for the B2 receptor, has been shown to decrease tumor growth and proliferation in many 
tumor types12,13, suggesting a pro-tumor role for the kinin B2 receptor. A less clear scenario is observed regarding 
the kinin B1 receptor. Although many reports showed that the B1 receptor contributes to tumor growth and pro-
gression, most of the studies have been done in systems that co-express B1 and B2 receptors. In fact, a cross-talk 
between those receptors has been described47, suggesting that a pro-tumor role of the B1 receptor might depend 
on B2 receptor expression. A recent report from our group using a B2-free cellular system showed that activation 
of kinin B1 receptor in the tumor cells resulted in less aggressive tumors, as evidenced by decreased proliferation, 
vascularization and metastasis, which ultimately improved animal survival17. Here, using a syngeneic model in a 
B1 receptor free microenvironment, we show that targeting the kinin B1 receptor from the host resulted in tum-
ors with unfavorable prognostic factors. Therefore, we believe that the host kinin B1 receptor may contribute to 
improve the host response against melanoma progression. Considering that metastatic melanoma still represents 
a great challenge in terms of aggressiveness and therapy resistance, targeting kinin B1 receptor may open new 
perspectives to improve the treatment of this disease.
Materials and Methods
Animal care and Ethics statement. All methods were performed in accordance with the guidelines of 
the Brazilian College of Animal Experimentation (COBEA), and all experimental protocols were approved by the 
Commission of Ethics in Animal Research (CETEA) from the Ribeirao Preto Medical School, University of São 
Paulo (CETEA, protocol 003/2011).
The B1 receptor-knockout mice (B1−/−) and the control littermates in a C57BL/6 genetic background were 
obtained from the Department of Biophysics, Federal University of São Paulo. The mice were bred and housed 
in a specific pathogen-free facility with the room temperature controlled at 25 °C in a 12 h light/dark cycle; mice 
received food and water ad libitum. Euthanasia was conducted by cervical dislocation at the study endpoint or 
earlier if animals met any of early removal criteria (lethargy hunched posture or ruffled coat).
Reagents. DNAse and SYBR Green reagents were purchased from Invitrogen (Carlsbad, CA, USA). The 
Improm-II reverse transcription system was purchased from Promega (Madison, WI, USA), and primers were 
purchased from IDT. Primary antibodies were purchased either from Millipore (Billerica, MA, USA), Cell 
Signaling Technology (Beverly, MA, USA), Abcam (Cambridge, United Kingdon) or Santa Cruz Biotechnology 
(Dallas, TX, USA); horseradish peroxidase-conjugated secondary antibodies were purchased from Millipore 
(Billerica, MA, USA), and the ECL kit was purchased from GE Healthcare (Buckinghamshire, England). Cell 
culture media and supplements were purchased from Gibco (Carlsbad, CA, USA).
Cell culture. B16F10 cells, which are derived from C57BL/6 mice, were cultured in Ham’s F10 media at pH 6.9 
supplemented with 10% FBS and 10 μ g/mL of gentamicin. All of the experiments were performed with 80–90% 
confluent cells.
In vivo studies. Primary tumor studies were performed using B16F10 melanoma cells. Tumors were induced 
injecting 300,000 cells in 100 μ L of PBS subcutaneously into the dorsal superior region of WT (n = 19) or B1−/− 
(n = 17) mice weighing approximately 25 g. Tumor size and animal weight were monitored daily for 22 days. At 
the study endpoint, animals were euthanized, and tumor samples were collected. Half of the tumor samples were 
immediately frozen in liquid nitrogen and pulverized for RNA and protein extraction. The remaining tumors 
were fixed in a 10% formaldehyde solution for histological analysis.
The metastatic model was induced by injecting 250,000 B16F10 melanoma cells in 100 μ L of PBS in the tail 
vein of WT (n = 11) or B1−/− (n = 8) mice weighing approximately 25 g. Animal weight was monitored daily for 
30 days. At the study endpoint, the animals were euthanized, and lungs were collected. The samples were fixed in 
a 10% formaldehyde solution for histological analysis.
Gene expression analyses. Total RNA was extracted with the TRIzol reagent from 100 mg of tumor 
sample, following the manufacturer’s instructions (Invitrogen). One microgram of total RNA was used for 
DNAse treatment and subsequent reverse transcription using the Improm-II protocol. For gene expression 
analysis, we performed quantitative PCR (qPCR) using 10–50 ng of cDNA and platinum SYBR Green qPCR 
supermix UDG with ROX reference dye (Invitrogen, Carlsbad, CA); results were analyzed using the ABI 
Prism 7000 sequence detection system. Transcripts were quantified relative to the housekeeping gene cyclo-
philin B using the ct method48. For gene expression assessment, we analyzed samples from 12 animals from 
each group, WT and B1−/−. The oligonucleotide primers used in the PCR analyses are listed in Supplementary 
Table S1.
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Western Blotting. Protein extraction from pulverized tissues was performed using the following lysis 
buffer: 10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 0.1% SDS; 1% Nonidet P-40; 1 mM 
PMSF, 10 μ g/mL leupeptin, 100 μ g/mL aprotinin, 10 mM benzamidine, 1 mM NaF, 1 mM sodium orthov-
anadate, and 1 mM DTT. The cell lysates were swirled for 30 minutes at 5 °C and centrifuged at 13500 rpm 
for 15 minutes (Eppendorf Centrifuge 5417 R). The supernatant was subsequently analyzed for total protein 
content using the Bradford quantification method (Bio-Rad, Hercules, CA). Fifty micrograms of protein was 
loaded into 12% acrylamide gels and separated by SDS-PAGE. Proteins were subsequently transferred onto 
a nitrocellulose membrane, blocked with 1% BSA and incubated with antibodies against VEGF (Abcam), 
β -actin (Millipore), phospho-ERK1/2 and ERK2 (Santa Cruz Biotechnology), phospho-Akt and Akt (Cell 
Signaling). Anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies and an 
ECL kit were used to visualize immunoblots. Quantification by densitometry was performed using ImageJ 
software49.
Histopathological analyses. Tumor samples were collected with adjacent tissue to preserve the tumor 
microenvironment and fixed in a 10% formaldehyde solution. Paraffin blocks were prepared, sectioned (4 μ m) 
and stained with hematoxylin and eosin. Slides were analyzed using a Leitz Aristoplan microscope (Germany) 
coupled to a Leica model DFC280 color camera (Heerbrugg, Switzerland). Mitotic cells and vessels from the 
primary tumor and from the lung were quantified at magnifications of 400x and 200x, respectively, across 10 
random, non-coincident microscopy fields. Skin samples were visualized at a magnification of 100x.
Immunohistochemistry. Formalin-fixed paraffin-embedded samples were sectioned into 4 μ m slices. 
Deparaffinized sections were subjected to antigen retrieval with citrate solution, pH 6.0 and treated with 3% 
hydrogen peroxide to inhibit endogenous peroxidase activity. After blocking slides with fetal bovine serum, 
sections were incubated overnight at 4 °C with a 1:100 dilution of CD4 monoclonal antibody (Abcam) and 
CD8 monoclonal antibody (Santa Cruz Biotechnology). Slides were treated with biotin-conjugated secondary 
anti-mouse antibody (Dako) and with horseradish peroxidase–conjugated avidin (Dako). Peroxidase activity 
was localized for all samples with 3,3′ -diaminobenzidine, counterstained with Harrys’s hematoxylin, dehydrated, 
cleared and mounted in mounting medium (Entellan, Merck).
Image Quantification. For evaluation of the presence CD4+and CD8+cells, we determined the surface 
density by optical density in the image analysis using the Leica QWin software (Leica Microsystems Image 
Solutions, Cambridge, UK) in conjunction with a Leica DMR microscope (Leica, Microsystems GmbH, Wetzlar, 
Germany), video camera (Leica Microsystems, Heerbrugg, Switzerland) and an online computer. The thresholds 
for CD4+and CD8+cells were established for each slide after enhancing the contrast to a point at which the cells 
were easily identified as a brown staining. Ten randomly chosen, non-coincident fields were measured for each 
group at 200x across a total area of 2.3 mm2.
Statistical analysis. Statistical analysis was performed using Student’s t-tests, two-tailed. Data are expressed 
as mean ± SEM. Differences between mean values were considered significant when p < 0.05.
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